Radix Dipsaci extract protects against Rosiglitazone induced bone loss
| Autor: | Ester Mary Pappiya, Krishnaraju Venkatesan, Vigneshwaran Easwaran, Premalatha Paulsamy, Khalid A Asseri, Kalpana Krishnaraju, R. Natarajan, Yahya I. Asiri, Noohu Abdulla Khan, Kumar Venkatesan, Ali Alqahtani, Kumarappan Chidambaram |
|---|---|
| Rok vydání: | 2021 |
| Předmět: | |
| Zdroj: | International Journal of Current Research in Chemistry and Pharmaceutical sciences. 8:15-21 |
| ISSN: | 2348-5221 2348-5213 |
| DOI: | 10.22192/ijcrcps.2021.08.09.003 |
| Popis: | The dried root of Dipsacus asperoides is known as Radix Dipsaci extract(RDE). It's a kidney-toning herbal medication with a lengthy track record of safe usage in the treatment of bone fractures and joint disorders. The drug rosiglitazone (RSG) causes an imbalance in bone remodelling, which results in increased apoptotic death of osteogenic cells and decreased bone production. The goal of this study was to investigate the effects of RDE on RSGinduced bone loss in diabetic rats in a systematic way. Five groups of six Wistar albino rats were studied: control (vehicle therapy), Streptozotocin (diabetes) group, RDE group, Rosiglitazone, and Rosiglitazone +RDE group. Insulin, oxidative stress, and bone turnover markers in the blood were all detected using ELISA tests. When compared to diabetic control rats, RDE therapy significantly raised insulin and osteocalcin levels. RDE may be able to prevent diabetic osteoporosis by boosting osteogenesis and lowering oxidative stress in the bone.These findings support the use of RDE as a bone loss inhibiting in diabetics. Well-designed clinical trials are likely to yield further scientific evidence on its bone-protective effects and safety. Keywords: Radix Dipsaci, Diabetic osteoporosis, Rosiglitazone. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|